THU0281 Do improvements in health-related quality of life during dmard treatment differ between psoriatic and rheumatoid arthritis patients? data from the prospective observational nor-dmard study, including baseline comparisons with norwegian general population controls
Authors: B. Michelsen, T. Uhlig, J. Sexton, H.B. Hammer, E.K. Kristianslund, G. Haugeberg, J.H. Loge, T.K. Kvien
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Only few longitudinal observational studies exist on the comparison of Health-related quality of life (HRQoL) between PsA and RA patients using the Medical Outcomes Survey Short Form-36 (SF-36), as well as with general population controls. <h3>Objectives</h3> The aims were 1) to explore if improvements in SF-36 scale scores differ between PsA and RA patients, 2) to compare proportions of PsA and RA patients achieving Minimum Clinically Important Improvements (MCII) in scale scores at 6 months follow-up<sup>1</sup>, 3) to compare HRQoL between RA, PsA patients and Norwegian general population controls. <h3>Methods</h3> We included first-time enrolled PsA and RA patients from the prospective observational multicenter NORwegian-Disease Modifying Anti-Rheumatic Drug (NOR-DMARD) study, starting conventional synthetic and/or biologic (cs/b) DMARDs between year 2000 and, 2012 as well as data from Norwegian general population controls.<sup>2</sup> Continuous variables were compared using independent t-test or Mann-Whitney U test as appropriate. Prespecified ANCOVA analyses adjusted for age and gender were performed to compare changes in scale scores from baseline to 6 months follow-up between PsA and RA patients. Radar diagram was made to visualise changes in scale scores (0 worst, 100 best) and bar charts to visualise improvements from baseline to 6 months as well as proportions of patients fulfilling MCII (≥5) in scale scores at 6 months. <h3>Results</h3> A total of 1515 PsA and 3898 RA patients as well as 2323 Norwegian general population controls<sup>2</sup> were included (mean (SD) age 48.1 (12.6)/55.9 (31.6)/44.9 (16.5) years, 50.3%/71.4%/51.3% women, respectively; median (25th-75th percentile) disease duration RA; 2.0 (0.1–9.6), PsA: 1.9 (0.1–11.0) years). Mean (SD) DAS28 was lower in PsA vs. RA patients at baseline (4.2 (1.3)/4.9 (1.4)) and at 6 months ((3.1 (1.3)/3.5 (1.5)), as well as median (25th-75th percentile) 28 swollen joint count at baseline (2 (1–5)/6 (3–10) and at 6 months (0 (0–2)/2 (0–4) follow-up, all p&lt;0.001. All scale scores were worse in PsA and RA compared with the general population (p≤0.001), but improved during cs/bDMARD treatment (figure 1a). The improvements were marginally better in RA versus PsA patients for bodily pain, vitality and mental health (figure 1b). Similar percentages of RA and PsA patients achieved MCII≥5 in scale scores from baseline until 6 months. <h3>Conclusions</h3> These findings indicate that PsA patients have at least as high disease burden in terms of HRQoL as RA patients, in spite of higher levels of joint inflammation in the RA patients. Improvements during treatment were overall similar, except for somewhat larger improvements in bodily pain, vitality and mental health in RA patients. Similar proportions of PsA and RA patients achieved MCII at 6 months. <h3>References</h3> [1] Strand, et al. Drugs2010;70:121–45 [2] Loge, et al. Scand J Soc Med1998;26:250–8. <h3>Disclosure of Interest</h3> None declared